RATIONALE: Nasopharyngeal carriage of Streptococcus pneumoniae is a prerequisite for invasive disease, but the majority of carriage episodes are asymptomatic and self-resolving. Interactions determining the development of carriage versus invasive disease are poorly understood but will influence the effectiveness of vaccines or therapeutics that disrupt nasal colonization. OBJECTIVES: We sought to elucidate immunological mechanisms underlying noninvasive pneumococcal nasopharyngeal carriage. METHODS: Pneumococcal interactions with human nasopharyngeal and bronchial fibroblasts and epithelial cells were investigated in vitro. A murine model of nasopharyngeal carriage and an experimental human pneumococcal challenge model were used to characterize immune responses in the airways during carriage. MEASUREMENTS AND MAIN RESULTS: We describe the previously unknown immunological basis of noninvasive carriage and highlight mechanisms whose perturbation may lead to invasive disease. We identify the induction of active transforming growth factor (TGF)-β1 by S. pneumoniae in human host cells and highlight the key role for TGF-β1 and T regulatory cells in the establishment and maintenance of nasopharyngeal carriage in mice and humans. We identify the ability of pneumococci to drive TGF-β1 production from nasopharyngeal cells in vivo and show that an immune tolerance profile, characterized by elevated TGF-β1 and high nasopharyngeal T regulatory cell numbers, is crucial for prolonged carriage of pneumococci. Blockade of TGF-β1 signaling prevents prolonged carriage and leads to clearance of pneumococci from the nasopharynx. CONCLUSIONS: These data explain the mechanisms by which S. pneumoniae colonize the human nasopharynx without inducing damaging host inflammation and provide insight into the role of bacterial and host constituents that allow and maintain carriage.
RATIONALE: Nasopharyngeal carriage of Streptococcus pneumoniae is a prerequisite for invasive disease, but the majority of carriage episodes are asymptomatic and self-resolving. Interactions determining the development of carriage versus invasive disease are poorly understood but will influence the effectiveness of vaccines or therapeutics that disrupt nasal colonization. OBJECTIVES: We sought to elucidate immunological mechanisms underlying noninvasive pneumococcal nasopharyngeal carriage. METHODS:Pneumococcal interactions with human nasopharyngeal and bronchial fibroblasts and epithelial cells were investigated in vitro. A murine model of nasopharyngeal carriage and an experimental humanpneumococcal challenge model were used to characterize immune responses in the airways during carriage. MEASUREMENTS AND MAIN RESULTS: We describe the previously unknown immunological basis of noninvasive carriage and highlight mechanisms whose perturbation may lead to invasive disease. We identify the induction of active transforming growth factor (TGF)-β1 by S. pneumoniae in human host cells and highlight the key role for TGF-β1 and T regulatory cells in the establishment and maintenance of nasopharyngeal carriage in mice and humans. We identify the ability of pneumococci to drive TGF-β1 production from nasopharyngeal cells in vivo and show that an immune tolerance profile, characterized by elevated TGF-β1 and high nasopharyngeal T regulatory cell numbers, is crucial for prolonged carriage of pneumococci. Blockade of TGF-β1 signaling prevents prolonged carriage and leads to clearance of pneumococci from the nasopharynx. CONCLUSIONS: These data explain the mechanisms by which S. pneumoniae colonize the human nasopharynx without inducing damaging host inflammation and provide insight into the role of bacterial and host constituents that allow and maintain carriage.
Authors: Ruben D Ramirez; Shelley Sheridan; Luc Girard; Mitsuo Sato; Young Kim; Jon Pollack; Michael Peyton; Ying Zou; Jonathan M Kurie; J Michael Dimaio; Sara Milchgrub; Alice L Smith; Rhonda F Souza; Laura Gilbey; Xi Zhang; Kenia Gandia; Melville B Vaughan; Woodring E Wright; Adi F Gazdar; Jerry W Shay; John D Minna Journal: Cancer Res Date: 2004-12-15 Impact factor: 12.701
Authors: Daniel R Neill; William R Coward; Jenna F Gritzfeld; Luke Richards; Francesc J Garcia-Garcia; Javier Dotor; Stephen B Gordon; Aras Kadioglu Journal: Am J Respir Crit Care Med Date: 2014-05-15 Impact factor: 21.405
Authors: Luke Richards; Daniela M Ferreira; Eliane N Miyaji; Peter W Andrew; Aras Kadioglu Journal: Immunobiology Date: 2009-12-28 Impact factor: 3.144
Authors: Daniela M Ferreira; Daniel R Neill; Mathieu Bangert; Jenna F Gritzfeld; Nicola Green; Adam K A Wright; Shaun H Pennington; Laura Bricio-Moreno; Laura Bricio Moreno; Adriana T Moreno; Eliane N Miyaji; Angela D Wright; Andrea M Collins; David Goldblatt; Aras Kadioglu; Stephen B Gordon Journal: Am J Respir Crit Care Med Date: 2013-04-15 Impact factor: 21.405
Authors: Daniel R Neill; William R Coward; Jenna F Gritzfeld; Luke Richards; Francesc J Garcia-Garcia; Javier Dotor; Stephen B Gordon; Aras Kadioglu Journal: Am J Respir Crit Care Med Date: 2014-05-15 Impact factor: 21.405
Authors: Angharad E Green; Deborah Howarth; Chrispin Chaguza; Haley Echlin; R Frèdi Langendonk; Connor Munro; Thomas E Barton; Jay C D Hinton; Stephen D Bentley; Jason W Rosch; Daniel R Neill Journal: Mol Biol Evol Date: 2021-05-19 Impact factor: 16.240
Authors: Caroline M Weight; Simon P Jochems; Hugh Adler; Daniela M Ferreira; Jeremy S Brown; Robert S Heyderman Journal: Front Cell Infect Microbiol Date: 2021-05-25 Impact factor: 5.293